Oncos Therapeutics Raises €4 Million from Healthcap to Develop Oncolytic Viruses into Cancer Treatments
News Apr 29, 2010
Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.
After treating 200 late stage cancer patients since 2007 with strong safety and efficacy results, Oncos has selected its modified oncolytic adenovirus CGTG-102 as its lead clinical candidate. “This is the first step to turn our Advanced Therapy Access Program results into cancer therapeutics”, comments Pekka Simula, CEO and co-founder.
“The results have been strong for late stage solid tumor cancers where routine therapies have failed. Time is critical in the treatment of cancer. We are confident that when treating earlier stage patients, our oncolytic virus therapy will prove even more significant”, continues Research Professor Akseli Hemminki, CSO and co-founder.
“Oncolytic viruses are maturing as a new treatment modality in cancer. Oncos, as one of the leading companies in the field, and combines very promising results in humans with strong science”, comments Dr Johan Christensen, partner at HealthCap.
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
Researchers Test Drug Transfer Using Placenta-On-A-ChipNews
Researchers have demonstrated the feasibility of their "organ-on-a-chip" platform in studying how drugs are transported across the human placental barrier.READ MORE
'Click Chemistry' Reactions Could Boost Cancer-Fighting Drug PotencyNews
Researchers at The Scripps Research Institute (TSRI) have developed a quick and easy way to simultaneously modify dozens of drugs or molecules to improve their disease-fighting properties.READ MORE